利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

66 条记录 (耗时 0.034 秒)

    Monoclonal Antibodies With Specificity For Fetal Erythroid Cells
    4.
    发明申请
    Monoclonal Antibodies With Specificity For Fetal Erythroid Cells 失效
    胎儿红细胞特异性单克隆抗体

    公开(公告)号：US20070276161A1

    公开(公告)日：2007-11-29

    申请号：US11661544

    申请日：2005-08-04

    申请人： Christine Hollmann ,  Silke Zimmermann ,  Stefan Stachelhaus ,  Winfried Albert

    发明人： Christine Hollmann ,  Silke Zimmermann ,  Stefan Stachelhaus ,  Winfried Albert

    IPC分类号： C07C213/10 ,  C07C215/02

    CPC分类号： C07C213/10 ,  C07C215/08

    摘要： Methods for improving color properties of triethanolamine, and triethanolamine compositions treated thereby, are disclosed, wherein the methods comprise: (a) providing a composition comprising triethanolamine; and (b) contacting the composition with an acid component and a basic component; wherein the acid component comprises an acid selected from the group consisting of phosphorous acid, hypophosphorous acid and mixtures thereof; and wherein the basic component comprises a compound selected from the group consisting of alkali metal hydroxides, alkaline earth metal hydroxides, ammonium hydroxides according to general formula (I), and mixtures thereof: [R1R2R3(2-hydroxyethyl)ammonium]hydroxide  (I) wherein R1, R2 and R3 each independently represents a C1-30 alkyl or a C2-10 hydroxyalkyl; with the proviso that where the basic component comprises an alkali metal hydroxide, the molar ratio of acid component:basic component is 1:0.1 to 1:1, and where the basic component comprises an alkaline earth metal hydroxide, the molar ratio of acid component:basic component is 1:0.05 to 1:0.5.

    摘要翻译： 公开了用于改善三乙醇胺的颜色特性和由此处理的三乙醇胺组合物的方法，其中所述方法包括：（a）提供包含三乙醇胺的组合物; 和（b）使组合物与酸组分和碱性组分接触; 其中所述酸组分包含选自亚磷酸，次磷酸及其混合物的酸; 并且其中所述碱性组分包括选自碱金属氢氧化物，碱土金属氢氧化物，根据通式（I）的氢氧化铵的化合物及其混合物：<？在线公式描述=“在线 公式“end =”lead“？> [R 1] R 2 R 3（2-羟乙基）铵]氢氧化物（I） in-line-formula description =“In-line Formulas”end =“tail”？>其中R 1，R 2和R 3， 各自独立地表示C 1〜30的烷基或C 2〜10 N个羟基烷基; 条件是碱性成分含有碱金属氢氧化物时，酸成分：碱成分的摩尔比为1:0.1〜1:1，碱性成分含有碱土金属氢氧化物时，酸成分 基本成分为1:0.05〜1:0.5。

    HYPERDISPERSANT FOR USE IN FLUOROCARBON COATING COMPOSITIONS
    5.
    发明申请
    HYPERDISPERSANT FOR USE IN FLUOROCARBON COATING COMPOSITIONS 有权
    用于氟碳涂料组合物的较高剂量

    公开(公告)号：US20070185249A1

    公开(公告)日：2007-08-09

    申请号：US11684823

    申请日：2007-03-12

    申请人： James Anderson ,  David Lindow ,  Donald Algrim

    发明人： James Anderson ,  David Lindow ,  Donald Algrim

    IPC分类号： C08G59/50 ,  C07C215/02

    CPC分类号： C08F220/14 ,  C08F220/32 ,  C08G59/184 ,  C08G59/24 ,  C08G59/3218 ,  C08G59/50 ,  C08G59/506 ,  C08L33/06 ,  C08L63/00 ,  C09D127/16 ,  C08L2666/02

    摘要： A hyperdispersant for use in a fluorocarbon coating composition is disclosed. The fluorocarbon coating composition generally comprises a fluorocarbon resin, a binder resin, a cross-linking agent, and the hyperdispersant. The hyperdispersant comprises the reaction product of a polyglycidyl oligomer and at least one amino compound. The polyglycidyl oligomer comprises a carbon chain having from 1 to 25 carbon atoms with at least one of an internal ether linkage and an internal ester linkage and comprises a plurality of epoxy groups. The at least one amino compound has a cyclic, heterocyclic, alkyl, or heteroalkyl structure substituted with at least one primary or secondary amine group for reacting with and opening at least one of the epoxy groups.

    摘要翻译： 公开了一种用于氟碳涂料组合物的超分散剂。 氟碳涂料组合物通常包含氟碳树脂，粘合剂树脂，交联剂和超分散剂。 超分散剂包括聚缩水甘油低聚物和至少一种氨基化合物的反应产物。 多缩水甘油低聚物包含具有1至25个碳原子的碳链和至少一个内部醚键和内部酯键，并且包含多个环氧基团。 所述至少一种氨基化合物具有被至少一个伯或仲胺基团取代的环状，杂环，烷基或杂烷基结构，用于与至少一种环氧基反应并打开至少一种环氧基。

    2,4-pentadienoic acid derivatives having retinoid-like biological activity
    8.
    发明授权
    2,4-pentadienoic acid derivatives having retinoid-like biological activity 失效
    具有类视黄醇样生物活性的2,4-戊二烯酸衍生物

    公开(公告)号：US5817836A

    公开(公告)日：1998-10-06

    申请号：US854868

    申请日：1997-05-12

    申请人： Vidyasagar Vuligonda ,  Roshantha A. Chandraratna

    发明人： Vidyasagar Vuligonda ,  Roshantha A. Chandraratna

    IPC分类号： A61K31/35 ,  A61K31/20 ,  A61K31/23 ,  A61K31/38 ,  A61K31/47 ,  A61P17/00 ,  A61P43/00 ,  C07C57/50 ,  C07C69/618 ,  C07C215/02 ,  C07C215/18 ,  C07C311/58 ,  C07C335/06 ,  C07C403/00 ,  C07D277/22 ,  C07D311/58 ,  C07D333/54 ,  C07D335/06 ,  C07D335/04 ,  C07D207/00 ,  C07D311/04 ,  C07D401/00

    CPC分类号： C07D333/54 ,  A61K31/20 ,  A61K31/23 ,  C07C57/50 ,  C07C69/618 ,  C07D311/58 ,  C07D335/06

    摘要： Compounds of Formula 1 ##STR1## wherein Z is selected from the group consisting of the radicals shown in Formula 2 and in Formula 3, ##STR2## Y is cycloalkyl or cycloalkenyl of 3 to 8 carbons optionally substituted with one or two R.sub.4 groups, or Y is selected from phenyl, pyridyl, thienyl, furyl, pyrrolyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, and imidazolyl, said groups being optionally substituted with one or two R.sub.4 groups, the divalent Y radical being substituted by the Z and --CR.sub.1 .dbd.CR.sub.1 --CR.sub.1 .dbd.CR.sub.1 groups on adjacent carbons; X is S, O, or NR.sub.5 ; n is 1 or 2; R.sub.1 and R.sub.2 independently are H, lower alkyl or fluoroalkyl; R.sub.3 is hydrogen, lower alkyl, Cl or Br; R.sub.4 is lower alkyl, fluoroalkyl or halogen; R.sub.5 is H or lower alkyl, and B is hydrogen, COOH or a pharmaceutically acceptable salt thereof, COOR.sub.8, CONR.sub.9 R.sub.10, --CH.sub.2 OH, CH.sub.2 OR.sub.11, CH.sub.2 OCOR.sub.11, CHO, CH(OR.sub.12).sub.2, CHOR.sub.13 O, --COR.sub.7, CR.sub.7 (OR.sub.12).sub.2, CR.sub.7 OR.sub.13 O, or tri-lower alkylsilyl, where R.sub.7 is an alkyl, cycloalkyl or alkenyl group containing 1 to 5 carbons, R.sub.8 is an alkyl group of 1 to 10 carbons, a cycloalkyl group of 5 to 10 carbons or trimethylsilylalkyl where the alkyl group has 1 to 10 carbons, or R.sub.8 is phenyl or lower alkylphenyl, R.sub.9 and R.sub.10 independently are hydrogen, an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5-10 carbons, or phenyl or lower alkylphenyl, R.sub.11 is lower alkyl, phenyl or lower alkylphenyl, R.sub.12 is lower alkyl, and R.sub.13 is divalent alkyl radical of 2-5 carbons, have retinoid like biological activity.

    摘要翻译： 式1的化合物其中Z选自由式2和式3所示的基团组成的组。式3 Y是3至8个碳的环烷基或环烯基，任选地 被一个或两个R 4基取代，或Y选自苯基，吡啶基，噻吩基，呋喃基，吡咯基，哒嗪基，嘧啶基，吡嗪基，噻唑基，恶唑基和咪唑基，所述基团任选被一个或两个R 4基团取代，二价 Y基团被相邻碳上的Z和-CR1 = CR1-CR1 = CR1基团取代; X是S，O或NR5; n为1或2; R1和R2独立地为H，低级烷基或氟代烷基; R3是氢，低级烷基，Cl或Br; R4是低级烷基，氟烷基或卤素; R 5是H或低级烷基，B是氢，COOH或其药学上可接受的盐，COOR8，CONR9R10，-CH2OH，CH2OR11，CH2OCOR11，CHO，CH（OR12）2，CHOR13O，-COR7，CR7（OR12） CR 7OR 13 O或三低级烷基甲硅烷基，其中R 7为含有1至5个碳的烷基，环烷基或烯基，R 8为碳原子数1至10的烷基，碳原子数为5至10的环烷基或烷基具有的三甲基甲硅烷基烷基 1至10个碳，或R8为苯基或低级烷基苯基，R9和R10独立地为氢，1-10个碳原子的烷基或5-10个碳原子的环烷基，或苯基或低级烷基苯基，R11为低级烷基， 苯基或低级烷基苯基，R12为低级烷基，R13为2-5个碳原子的二价烷基，具有类视黄醇类生物活性。

    2,4-pentadienoic acid derivatives having retinoid-like biological activity
    10.
    发明授权
    2,4-pentadienoic acid derivatives having retinoid-like biological activity 失效
    具有类视黄醇样生物活性的2,4-戊二烯酸衍生物

    公开(公告)号：US5663367A

    公开(公告)日：1997-09-02

    申请号：US656137

    申请日：1996-05-31

    申请人： Vidyasagar Vuligonda ,  Roshantha A. Chandraratna

    发明人： Vidyasagar Vuligonda ,  Roshantha A. Chandraratna

    IPC分类号： A61K31/35 ,  A61K31/20 ,  A61K31/23 ,  A61K31/38 ,  A61K31/47 ,  A61P17/00 ,  A61P43/00 ,  C07C57/50 ,  C07C69/618 ,  C07C215/02 ,  C07C215/18 ,  C07C311/58 ,  C07C335/06 ,  C07C403/00 ,  C07D277/22 ,  C07D311/58 ,  C07D333/54 ,  C07D335/06 ,  C07D333/12 ,  C07D307/40 ,  C07D307/56 ,  C07D333/22

    CPC分类号： C07D333/54 ,  A61K31/20 ,  A61K31/23 ,  C07C57/50 ,  C07C69/618 ,  C07D311/58 ,  C07D335/06

    摘要： Compounds of Formula 1 ##STR1## wherein Z is selected from the group consisting of the radicals shown in Formula 2 and in Formula 3, ##STR2## Y is cycloalkyl or cycloalkenyl of 3 to 8 carbons optionally substituted with one or two R.sub.4 groups, or Y is selected from phenyl, pyridyl, thienyl, furyl, pyrrolyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, and imidazolyl, said groups being optionally substituted with one or two R.sub.4 groups, the divalent Y radical being substituted by the Z and --CR.sub.1 .dbd.CR.sub.1 --CR.sub.1 .dbd.CR.sub.1 groups on adjacent carbons; X is S, O, or NR.sub.5 ; n is 1 or 2; R.sub.1 and R.sub.2 independently are H, lower alkyl or fluoroalkyl; R.sub.3 is hydrogen, lower alkyl, Cl or Br; R.sub.4 is lower alkyl, fluoroalkyl or halogen; R.sub.5 is H or lower alkyl, and B is hydrogen, COOH or a pharmaceutically acceptable salt thereof, COOR.sub.8, CONR.sub.9 R.sub.10, --CH.sub.2 OH, CH.sub.2 OR.sub.11, CH.sub.2 OCOR.sub.11, CHO, CH(OR.sub.12).sub.2, CHOR.sub.13 O, --COR.sub.7, CR.sub.7 (OR.sub.12).sub.2, CR.sub.7 OR.sub.13 O, or tri-lower alkylsilyl, where R.sub.7 is an alkyl, cycloalkyl or alkenyl group containing 1 to 5 carbons, R.sub.8 is an alkyl group of 1 to 10 carbons, a cycloalkyl group of 5 to 10 carbons or trimethylsilylalkyl where the alkyl group has 1 to 10 carbons, or R.sub.8 is phenyl or lower alkylphenyl, R.sub.9 and R.sub.10 independently are hydrogen, an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5-10 carbons, or phenyl or lower alkylphenyl, R.sub.11 is lower alkyl, phenyl or lower alkylphenyl, R.sub.12 is lower alkyl, and R.sub.13 is divalent alkyl radical of 2-5 carbons, have retinoid like biological activity.

    摘要翻译： 式1的化合物其中Z选自由式2和式3所示的基团组成的组。式3 Y是3至8个碳的环烷基或环烯基，任选地 被一个或两个R 4基取代，或Y选自苯基，吡啶基，噻吩基，呋喃基，吡咯基，哒嗪基，嘧啶基，吡嗪基，噻唑基，恶唑基和咪唑基，所述基团任选被一个或两个R 4基团取代，二价 Y基团被相邻碳上的Z和-CR1 = CR1-CR1 = CR1基团取代; X是S，O或NR5; n为1或2; R1和R2独立地为H，低级烷基或氟代烷基; R3是氢，低级烷基，Cl或Br; R4是低级烷基，氟烷基或卤素; R 5是H或低级烷基，B是氢，COOH或其药学上可接受的盐，COOR8，CONR9R10，-CH2OH，CH2OR11，CH2OCOR11，CHO，CH（OR12）2，CHOR13O，-COR7，CR7（OR12） CR 7OR 13 O或三低级烷基甲硅烷基，其中R 7为含有1至5个碳的烷基，环烷基或烯基，R 8为碳原子数1至10的烷基，碳原子数为5至10的环烷基或烷基具有的三甲基甲硅烷基烷基 1至10个碳，或R8为苯基或低级烷基苯基，R9和R10独立地为氢，1-10个碳原子的烷基或5-10个碳原子的环烷基，或苯基或低级烷基苯基，R11为低级烷基， 苯基或低级烷基苯基，R12为低级烷基，R13为2-5个碳原子的二价烷基，具有类视黄醇类生物活性。